Evidence map›Paper›PMID 27552316›Full record

ArticleBiomaterials2016

Direct 3D bioprinting of perfusable vascular constructs using a blend bioink.

Weitao Jia, P Selcan Gungor-Ozkerim, Yu Shrike Zhang, Kan Yue, Kai Zhu, Wanjun Liu, Qingment Pi, Batzaya Byambaa, Mehmet Remzi Dokmeci, Su Ryon Shin and 1 more

Erratum issuedAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 322 papers.

0numbers the graph read from it
0cells of the map it votes in
322citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

322 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. 3D Bioprinting Strategies in Autoimmune Disease Models.International journal of molecular sciences · 2025
    Review
  18. Article
  19. Article
  20. Article

262 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors.

Weitao JiaBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Orthopedic Surgery, Shanghai Jiaotong University Affiliated Sixth People's Hospital, Shanghai Jiaotong University, Shanghai, 200233, PR China.
P Selcan Gungor-OzkerimBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Yu Shrike ZhangBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA. Electronic address: yszhang@research.bwh.harvard.edu.
Kan YueBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Kai ZhuBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Department of Cardiac Surgery, Zhongshan Hospital, Fudan University, Shanghai Institute of Cardiovascular Disease, Shanghai, 200032, PR China.
Wanjun LiuBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Qingment PiBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Batzaya ByambaaBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA.
Mehmet Remzi DokmeciBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA.
Su Ryon ShinBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA. Electronic address: sshin4@partners.org.
Ali KhademhosseiniBiomaterials Innovation Research Center, Division of Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Cambridge, MA, 02139, USA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA, 02139, USA; Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, 02115, USA; Department of Bioindustrial Technologies, College of Animal Bioscience and Technology, Konkuk University, Seoul, 143-701, Republic of Korea; Department of Physics, King Abdulaziz University, Jeddah, 21569, Saudi Arabia. Electronic address: alik@bwh.harvard.edu.

Funding

Microengineered Osteons for Bone Tissue EngineeringR01AR057837 · NIAMS · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2010 to 2018
$5.1M
3D combinatorial microenvironments for effective cell based therapyR01HL099073 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI, LIAO, RONGLIH · 2010 to 2013
$2.6M
Microfabricated Vascularized 3D Tissue Engineered ConstructsR01HL092836 · NHLBI · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2008 to 2012
$2.4M
High-Throughput Microenvironment Regulation for ChondrogenesisR01AR066193 · NIAMS · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ALSBERG, EBEN, KHADEMHOSSEINI, ALI · 2015 to 2020
$2.1M
Engineering Vascularized Bone Tissues By Microfabrication And ScaffoldingR01DE021468 · NIDCR · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI YANG, YUNZHI · 2011 to 2014
$1.8M
Catheter guided endovascular electric field ablation for thrombosis therapy.R21EB021148 · NIBIB · MAYO CLINIC ARIZONA · PI KHADEMHOSSEINI, ALI, OKLU, RAHMI · 2016 to 2017
$485k
Smart wound dressing for treating chronic diabetic ulcersR21EB022403 · NIBIB · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2016 to 2017
$484k
Angiogenic Biomaterials as Dermal Scaffolds to Enhance Diabetic Wound HealingR21AR068258 · NIAMS · BRIGHAM AND WOMEN'S HOSPITAL · PI KHADEMHOSSEINI, ALI · 2015 to 2016
$412k
Recapitulating Ductal Carcinoma on a Chip for Personalized Breast Cancer TherapyK99CA201603 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ZHANG, Y. SHRIKE · 2016 to 2017
$356k
NCI NIH HHS K99 CA201603NHLBI NIH HHS R01 HL092836NHLBI NIH HHS R01 HL099073NIAMS NIH HHS R01 AR057837NIAMS NIH HHS R01 AR066193NIAMS NIH HHS R21 AR068258NIBIB NIH HHS R21 EB021148NIBIB NIH HHS R21 EB022403NIDCR NIH HHS R01 DE021468
6 · The paper itself

Abstract

Despite the significant technological advancement in tissue engineering, challenges still exist towards the development of complex and fully functional tissue constructs that mimic their natural counterparts. To address these challenges, bioprinting has emerged as an enabling technology to create highly organized three-dimensional (3D) vascular networks within engineered tissue constructs to promote the transport of oxygen, nutrients, and waste products, which can hardly be realized using conventional microfabrication techniques. Here, we report the development of a versatile 3D bioprinting strategy that employs biomimetic biomaterials and an advanced extrusion system to deposit perfusable vascular structures with highly ordered arrangements in a single-step process. In particular, a specially designed cell-responsive bioink consisting of gelatin methacryloyl (GelMA), sodium alginate, and 4-arm poly(ethylene glycol)-tetra-acrylate (PEGTA) was used in combination with a multilayered coaxial extrusion system to achieve direct 3D bioprinting. This blend bioink could be first ionically crosslinked by calcium ions followed by covalent photocrosslinking of GelMA and PEGTA to form stable constructs. The rheological properties of the bioink and the mechanical strengths of the resulting constructs were tuned by the introduction of PEGTA, which facilitated the precise deposition of complex multilayered 3D perfusable hollow tubes. This blend bioink also displayed favorable biological characteristics that supported the spreading and proliferation of encapsulated endothelial and stem cells in the bioprinted constructs, leading to the formation of biologically relevant, highly organized, perfusable vessels. These characteristics make this novel 3D bioprinting technique superior to conventional microfabrication or sacrificial templating approaches for fabrication of the perfusable vasculature. We envision that our advanced bioprinting technology and bioink formulation may also have significant potentials in engineering large-scale vascularized tissue constructs towards applications in organ transplantation and repair.

Indexed as

Batch Cell Culture TechniquesBioartificial OrgansBioreactorsBlood VesselsCells, CulturedEndothelial CellsEquipment DesignHumansInkNeovascularization, PhysiologicOrgan Culture TechniquesPerfusionPrinting, Three-DimensionalTissue EngineeringTissue Scaffolds3D BioprintingBioinkEndothelial cellsMesenchymal stem cellsPerfusable hollow tube

Identifiers

PMID27552316
PMCPMC5300870

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.